Hematologic Oncology Update

View Top 200 Chart

Back to Rankings Page

Health & Fitness
**Hematologic Oncology Update**

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

Latest Episodes:

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program Sep 02, 2026

Show notes

Featuring perspectives from Dr William G Wierda, including the following topics:

Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
Sequencing Road Map (12:39)
Key Datasets — Pirtobrutinib (21:08)
Investigator Survey (34:09)
Chimeric Antigen Receptor T-Cell Therapy (45:08)
Other Novel Therapy Approaches (49:58)
EHA 2026 (54:45)

CME information and select publications

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances Aug 26, 2026

Show notes

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:

Introduction: Lymphoma Survivorship (0:00)
Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)
Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)

CME information and select publications

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances Aug 17, 2026

Show notes

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:

Introduction (00:00)
Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
ASCO and EHA 2026 (46:37)

CME information and select publications

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies Aug 13, 2026

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)

CME information and select publications

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting Aug 11, 2026

Show notes

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:

Introduction (0:00)
The Biopathophysiology of Myelofibrosis (MF) (2:19)
Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
Upcoming at European Hematology Association (EHA) 2026 (49:22)

CME information and select publications

Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Aug 05, 2026

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress Aug 03, 2026

Show notes

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

Introduction (00:00)
Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
Utility of Belantamab Mafodotin in R/R MM (49:29)
Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1 Jul 27, 2026

Show notes

Featuring perspectives from Dr Mazyar Shadman, including the following topics:

The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2 Jul 27, 2026

Show notes

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 22, 2026

Show notes

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

Introduction(0:00)
Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)

CME information and select publications